Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1987-12-18
1991-09-10
Weimar, Elizabeth C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
435 6952, 4351723, 935 10, 536 27, C07K 1506, C07K 1300
Patent
active
050475053
ABSTRACT:
Plasmid pUC8 and DNA coding for hIL-1.beta. are used to construct hybrid plasmids capable of high level expression in E. coli of soluble proteins, including mature hIL-1.beta. and derivatives of mature hIL-1.beta. having amino acid substitutions and insertions at one or all of positions 1 to 4 at the amino terminus. Derivatives of hIL-1.beta. with alterations at the N-terminus have been produced which have either enhanced or decreased bioactivity compared to native monocyte derived hIL-1.beta..
REFERENCES:
patent: 4468464 (1984-08-01), Cohen et al.
Mosley et al., Proceedings, National Academy Science, U.S.A., vol. 84, pp. 4572-4576, Jul. 1987.
Horuk, et al., Journal of Biological Chemistry, vol. 262, No. 34, pp. 16275-16278, 1987.
Clark-Lewis et al. 1986, Science. 231, 134-139.
March et al., Nature, 315:641-647, 20 Jun. 1985.
Kronheim et al., Biotechnology, 4:1078-1082, Dec. 1986.
Auron et al., Proc. Natl. Acad. Sci., U.S.A., 81:7907-7911 (1984).
Dinarello et al., J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Rossenwasser et al., Proc. Natl. Acad. Sci., U.S.A., 83:5243-5246 (Jul. 1987).
Gubler et al., J. Immunology, 136:2492-2497 (1986).
Vieira et al., Gene, 19:259-268 (1982).
Catalog of Pharmacia Laboratories of Piscataway, N.J., pp. 60, 136 & 139.
Thornton, et al., J. Mol. Biol. (1963):167, 443-460.
Oppenheim, et al., Immunology Today, vol. 7, No. 2, pp. 45-56.
Bachmair, et al., Science, vol. 34, pp. 179-186 (1986).
Killian et al., J. Immunology, vol. 136, No. 12, pp. 4509-4514 (1986).
Dower, et al., Nature, vol. 324, pp. 266-268.
Wingfield, et al., Eur. J. Biochem, 160:491-497 (1986).
Meyers et al., J. Biol. Chem., vol. 62, No. 23, pp. 11176-11181 (1987).
Tocci, et al., J. Immunology, vol. 138, pp. 1109-1114 (1987).
Dinarello, Bull. Inst. Pasteur, 1987:85, 267-285.
Dinarello, FASEB J., vol. 2, 108-115 (1988).
Mosley, et al., Proc. Natl. Acad. Sci., U.S.A., vol. 84, pp. 4572-4576 (Jul. 1987).
Vierra et al. (1982) Gene 19, 259-268.
March et al. (1985) Nature 315, 614-647.
Int. Biotech. Inc. Catalog (1986-1987) pp. 117-120.
Wingfield et al. (1986) Eur. J. Biochem. 160, 491-497.
Auron et al. (1984) Proc. Natl. Acad. Sci. U.S.A. 84, 7907-7911.
Thornton et al. (1983) 167, 443-460.
Bachmair et al. (1986) Science 34, 179-186.
Huang et al., FEBS Letters, vol. 223, No. 2, Nov. 2, 1987, pp. 294-298.
Huang, et al., Mol. Biol. Med. (1974), vol. 4, pp. 169-181.
Du Pont Merck Pharmaceutical Company
Low Christopher
Weimar Elizabeth C.
LandOfFree
High level expression in E. coli of soluble mature HIL-1beta and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High level expression in E. coli of soluble mature HIL-1beta and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High level expression in E. coli of soluble mature HIL-1beta and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-540897